A talented endophytic Streptomyces sp. PH9030 is derived from the medicinal plant Kadsura coccinea (Lem.) A.C. Smith. The undescribed naphthoquinone naphthgeranine G (5) and seven previously identified compounds, 6–12, were obtained from Streptomyces sp. PH9030. The structure of 5 was identified by comprehensive examination of its HRESIMS, 1D NMR, 2D NMR and ECD data. The inhibitory activities of all the compounds toward α-glucosidase and their antibacterial properties were investigated. The α-glucosidase inhibitory activities of 5, 6, 7 and 9 were reported for the first time, with IC₅₀ values ranging from 66.4 ± 6.7 to 185.9 ± 0.2 μM, as compared with acarbose (IC₅₀ = 671.5 ± 0.2 μM). The molecular docking and molecular dynamics analysis of 5 with α-glucosidase further indicated that it may have a good binding ability with α-glucosidase. Both 9 and 12 exhibited moderate antibacterial activity against methicillin-resistant Staphylococcus aureus, with minimum inhibitory concentration (MIC) values of 16 μg/mL. These results indicate that 5, together with the naphthoquinone scaffold, has the potential to be further developed as a possible inhibitor of α-glucosidase.

An essential multiprotein complex in the innate immune system is the NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome. Through the coordination of upstream sensors and the adaptor protein ASC, which converge on the inflammasome complex in response to pathogens and cellular homeostatic disruptions, a broad range of metabolic danger signals activate the NLRP3 inflammasome. New research demonstrates the anti-inflammatory qualities of natural products, suggesting that they could be used as supplemental treatments for a number of chronic inflammatory conditions, such as diabetes mellitus and cardiovascular disorders. The literature related to inhibition of the NLRP3 inflammasome was compiled using keywords such as “NLRP3 Inflammasome”, “Natural products”, and “Inhibitor” from scientific databases, including “China Knowledge Resource Integrated Databases (CNKI)”, “Google Scholar”, “PubMed”, and “Web of Science” and so on, covering the period from 1997 to 2025. Herbal remedies have shown protection against the activation of the NLRP3 inflammasome. For the treatment of chronic inflammatory illnesses, natural products’ capacity to prevent NLRP3 inflammasome activation offers a novel and practical therapeutic approach. The impact of natural compounds made from medicinal plants on NLRP3 inflammasome activation and their underlying mechanisms of action are the main topics of this review.

Pseudomonas syringae functions as a model phytopathogen causing numerous crop diseases, resulting in substantial economic losses in global agriculture. Presently, management of P. syringae predominantly depends on chemical pesticides; however, their prolonged application has contributed to escalating resistance and environmental contamination, highlighting urgent requirement for sustainable biological control approaches. In this review, we examine recent advances in the utilization and mechanistic understanding of natural products derived from plants, animals, and microorganisms for the control of P. syringae. Plant-derived compounds—including flavonoids, terpenoids, and alkaloids—inhibit P. syringae infection by targeting the bacterial type III secretion system (T3SS), disrupting cell membrane integrity, promoting reactive oxygen species (ROS) accumulation, and activating plant immune signaling pathways such as salicylic acid (SA) and jasmonic acid (JA) cascades. Animal-derived substances, such as chitosan, propolis, and antimicrobial peptides, primarily exert antibacterial effects through membrane disruption and immune system stimulation. Microbial-derived natural products contribute to synergistic disease suppression by modulating host immunity and interfering with the pathogen’s quorum sensing mechanisms. Evidence indicates that these natural products possess multi-target antimicrobial properties, offering a rich repository of candidate molecules, such as baicalein, lignans, and carvacrol, for the development of eco-friendly antibacterial agents. Future investigations should focus on detailed characterization of these bioactive compounds and their specific disease targets, optimization of extraction methodologies to improve stability and bioavailability, and comprehensive assessment of environmental safety to advance the industrial implementation of sustainable biocontrol strategies